Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples